Cybin (OTCMKTS:CYBN) Trading Down 1.6% – What’s Next?

Cybin Inc. (OTCMKTS:CYBNGet Free Report) shares were down 1.6% on Thursday . The company traded as low as $5.95 and last traded at $6.10. Approximately 521,009 shares were traded during trading, an increase of 33% from the average daily volume of 390,822 shares. The stock had previously closed at $6.20.

Cybin Stock Down 1.6%

The company has a 50 day moving average of $6.50 and a 200 day moving average of $7.08. The firm has a market cap of $153.65 million, a price-to-earnings ratio of -32.11 and a beta of 0.63.

About Cybin

(Get Free Report)

Cybin Inc, a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation.

Featured Stories

Receive News & Ratings for Cybin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cybin and related companies with MarketBeat.com's FREE daily email newsletter.